Lxo Ireland Designated Activity Patent-Cliff Exposure & CMS Drug Spending Portfolio
Lxo Ireland Designated Activity (US): 3 reconciled FDA prescription therapies (89.4% 2025 to 2030 cliff risk), $1.0M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 3 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 89.4% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $1.0M |
| 2024 Medicare Part D Spend | $868K |
| 2024 Medicaid Spend | $170K |
| California HCAI SB 17 Filings | 8 WAC filings (max 29.5% 2-yr change) |